Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 37% discount to our quantitative fair value estimate of $27.60 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 2.9, which lies in the bottom 30% compared with global peers. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

The company's balance sheet is an additional encouraging factor. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 6.8, a core component of leverage, ranks in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which further promotes our favorable price/fair value ratio.

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.